Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription


2 AJR Am J Roentgenol
1 Am J Clin Pathol
1 Am J Pathol
2 Am J Surg
5 Am J Surg Pathol
2 Ann Oncol
3 Ann Surg
3 Ann Surg Oncol
2 Anticancer Res
4 BMC Cancer
2 Br J Cancer
2 Breast Cancer
1 Breast Cancer (Auckl)
4 Breast Cancer Res
14 Breast Cancer Res Treat
5 Breast J
1 Cancer
3 Clin Breast Cancer
1 Clin Cancer Res
1 Eur J Cancer
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Clin Invest
2 J Natl Cancer Inst
1 J Surg Oncol
1 Oncology
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. DANG PA, Wang A, Senapati GM, Ip IK, et al
    Comparing Tumor Characteristics and Rates of Breast Cancers Detected by Screening Digital Breast Tomosynthesis and Full-Field Digital Mammography.
    AJR Am J Roentgenol. 2019 Oct 15:1-6. doi: 10.2214/AJR.18.21060.
    PubMed         Abstract available

  2. SIPPO DA, Rutledge GM, Burk KS, Mercaldo SF, et al
    Effect of Background Parenchymal Enhancement on Cancer Risk Across Different High-Risk Patient Populations Undergoing Screening Breast MRI.
    AJR Am J Roentgenol. 2019 Mar 19:1-7. doi: 10.2214/AJR.18.20566.
    PubMed         Abstract available

    Am J Clin Pathol

  3. BULTE JP, Halilovic A, Burgers LJM, Diepenbroek CJM, et al
    Accelerated Tissue Processing With Minimal Formalin Fixation Time for 9-Gauge Vacuum-Assisted Breast Biopsy Specimens.
    Am J Clin Pathol. 2020;153:58-65.
    PubMed         Abstract available

    Am J Pathol

  4. KOCAK A, Heselmeyer-Haddad K, Lischka A, Hirsch D, et al
    High levels of chromosomal copy number alterations and TP53 mutations correlate with poor outcome in younger breast cancer patients.
    Am J Pathol. 2020 May 13. pii: S0002-9440(20)30238.
    PubMed         Abstract available

    Am J Surg

  5. WIENS N, Hoffman DI, Huang CY, Nayak A, et al
    Clinical characteristics and outcomes of benign, atypical, and malignant breast adenomyoepithelioma: a single institution's experience.
    Am J Surg. 2020;219:651-654.
    PubMed         Abstract available

  6. MACFIE R, Aks C, Panwala K, Johnson N, et al
    Breast conservation therapy confers survival and distant recurrence advantage over mastectomy for stage II Triple Negative Breast cancer.
    Am J Surg. 2020 Apr 30. pii: S0002-9610(20)30220.
    PubMed         Abstract available

    Am J Surg Pathol

  7. ZHONG E, Cheng E, Goldfischer M, Hoda SA, et al
    Papillary Lesions of the Male Breast: A Study of 117 Cases and Brief Review of the Literature Demonstrate a Broad Clinicopathologic Spectrum.
    Am J Surg Pathol. 2020;44:68-76.
    PubMed         Abstract available

  8. CLINTON LK, Plesec T, Goldblum JR, Hajifathalian K, et al
    Specific Histopathologic Features Aid in Distinguishing Diffuse-type Gastric Adenocarcinoma From Metastatic Lobular Breast Carcinoma.
    Am J Surg Pathol. 2020;44:77-86.
    PubMed         Abstract available

  9. SLODKOWSKA E, Xu B, Kos Z, Bane A, et al
    Predictors of Outcome in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study.
    Am J Surg Pathol. 2020;44:214-223.
    PubMed         Abstract available

  10. GRABENSTETTER A, Brennan S, Salagean ED, Morrow M, et al
    Flat Epithelial Atypia in Breast Core Needle Biopsies With Radiologic-Pathologic Concordance: Is Excision Necessary?
    Am J Surg Pathol. 2020;44:182-190.
    PubMed         Abstract available

  11. SHABIHKHANI M, Simpson JF, White MJ, Cimino-Mathews A, et al
    Artifactual Displacement of Ductal Carcinoma In Situ (ADDCIS) (Toothpaste Effect): A Mimicker of Invasive Ductal Carcinoma.
    Am J Surg Pathol. 2020;44:120-128.
    PubMed         Abstract available

    Ann Oncol

  12. HILBERS FS, Aftimos P
    Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?
    Ann Oncol. 2020 May 15. pii: S0923-7534(20)39818.

  13. RUGO HS, Andre F, Yamashita T, Cerda H, et al
    Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.
    Ann Oncol. 2020 May 13. pii: S0923-7534(20)39798.
    PubMed         Abstract available

    Ann Surg

  14. SAMIEI S, van Nijnatten TJA, de Munck L, Keymeulen KBMI, et al
    Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy.
    Ann Surg. 2020;271:574-580.
    PubMed         Abstract available

  15. POLITI MC, Lee CN, Philpott-Streiff SE, Foraker RE, et al
    A Randomized Controlled Trial Evaluating the BREASTChoice Tool for Personalized Decision Support About Breast Reconstruction After Mastectomy.
    Ann Surg. 2020;271:230-237.
    PubMed         Abstract available

  16. THOMPSON CK, Lee MK, Baker JL, Attai DJ, et al
    Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak.
    Ann Surg. 2020 May 20. doi: 10.1097/SLA.0000000000004027.

    Ann Surg Oncol

  17. GREENUP RA, Prakash I, Sorenson C
    "Choosing Wisely" in Breast Cancer Surgery: Drivers of Low Value Care.
    Ann Surg Oncol. 2020 May 15. pii: 10.1245/s10434-020-08584.

  18. FAN B, Pardo JA, Serres S, Alapati AC, et al
    Role of Sentinel Lymph Node Biopsy in Microinvasive Breast Cancer.
    Ann Surg Oncol. 2020 May 19. pii: 10.1245/s10434-020-08606.
    PubMed         Abstract available

  19. MAGNONI F, Intra M
    ASO Author Reflections: Future View: A Recent Scientific Contribution Towards a Staging Revision of Contralateral Axillary Lymph Node Metastases from Breast Cancer.
    Ann Surg Oncol. 2020 May 19. pii: 10.1245/s10434-020-08612.

    Anticancer Res

  20. YAMAMOTO J, Murata T, Sugisawa N, Higuchi T, et al
    Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer Res. 2020;40:2475-2479.
    PubMed         Abstract available

  21. YAMAMOTO J, Murata T, Tashiro Y, Higuchi T, et al
    A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
    Anticancer Res. 2020;40:2509-2514.
    PubMed         Abstract available

    BMC Cancer

    Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
    BMC Cancer. 2020;20:440.
    PubMed         Abstract available

  23. NAUGHTON MJ, Beverly Hery CM, Janse SA, Naftalis EZ, et al
    Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18 months of diagnosis.
    BMC Cancer. 2020;20:432.
    PubMed         Abstract available

  24. WESOLOWSKI R, Stiff A, Quiroga D, McQuinn C, et al
    Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    BMC Cancer. 2020;20:445.
    PubMed         Abstract available

  25. IWASE T, Harano K, Masuda H, Kida K, et al
    Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    BMC Cancer. 2020;20:430.
    PubMed         Abstract available

    Br J Cancer

  26. ORLANDELLA FM, Mariniello RM, Mirabelli P, De Stefano AE, et al
    miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUAK1 kinase.
    Br J Cancer. 2020 May 18. pii: 10.1038/s41416-020-0884.
    PubMed         Abstract available

  27. CHEUNG SM, Husain E, Masannat Y, Miller ID, et al
    Lactate concentration in breast cancer using advanced magnetic resonance spectroscopy.
    Br J Cancer. 2020 May 19. pii: 10.1038/s41416-020-0886.
    PubMed         Abstract available

    Breast Cancer

  28. TSUDA H, Tsugawa K, Akiyama F, Horii R, et al
    Correction to: Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition).
    Breast Cancer. 2020 May 19. pii: 10.1007/s12282-020-01106.
    PubMed         Abstract available

  29. SHIZUKU M, Shibata M, Okumura M, Takeuchi D, et al
    Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases.
    Breast Cancer. 2020 May 15. pii: 10.1007/s12282-020-01109.
    PubMed         Abstract available

    Breast Cancer (Auckl)

  30. MOUH FZ, Slaoui M, Razine R, El Mzibri M, et al
    Clinicopathological, Treatment and Event-Free Survival Characteristics in a Moroccan Population of Triple-Negative Breast Cancer.
    Breast Cancer (Auckl). 2020;14:1178223420906428.
    PubMed         Abstract available

    Breast Cancer Res

  31. AL-ANSARI MM, Al-Saif M, Arafah M, Eldali AM, et al
    Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients.
    Breast Cancer Res. 2020;22:49.
    PubMed         Abstract available

  32. KONAN HP, Kassem L, Omarjee S, Surmieliova-Garnes A, et al
    ERalpha-36 regulates progesterone receptor activity in breast cancer.
    Breast Cancer Res. 2020;22:50.
    PubMed         Abstract available

  33. JAYARAMAN S, Hou X, Kuffel MJ, Suman VJ, et al
    Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Breast Cancer Res. 2020;22:51.
    PubMed         Abstract available

  34. GOLDSTEIN LJ, Perez RP, Yardley D, Han LK, et al
    Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
    Breast Cancer Res. 2020;22:52.
    PubMed         Abstract available

    Breast Cancer Res Treat

  35. LEE HB, Han W, Kim SY, Cho N, et al
    Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
    Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05678.
    PubMed         Abstract available

  36. ZHONG Y, Xu Y, Zhou Y, Mao F, et al
    Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.
    Breast Cancer Res Treat. 2020 May 19. pii: 10.1007/s10549-020-05686.
    PubMed         Abstract available

  37. KOUMARIANOU A, Makrantonakis P, Zagouri F, Papadimitriou C, et al
    ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 16. pii: 10.1007/s10549-020-05677.
    PubMed         Abstract available

  38. BACH L, Kostev K, Schiffmann L, Kalder M, et al
    Association between thyroid gland diseases and breast cancer: a case-control study.
    Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05675.
    PubMed         Abstract available

  39. LI Y, Qin J, Wu J, Dai X, et al
    High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
    Breast Cancer Res Treat. 2020 May 18. pii: 10.1007/s10549-020-05671.
    PubMed         Abstract available

  40. TOMAO F, Verrico M, Tomao S
    Fertility and reproduction in breast cancer patients.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05676.

  41. ALMSTEDT K, Mendoza S, Otto M, Battista MJ, et al
    EndoPredict((R)) in early hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05688.
    PubMed         Abstract available

  42. DEUTSCH TM, Riethdorf S, Fremd C, Feisst M, et al
    HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05687.
    PubMed         Abstract available

  43. LOFTEROD T, Frydenberg H, Flote V, Eggen AE, et al
    Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05679.
    PubMed         Abstract available

    Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
    Breast Cancer Res Treat. 2020 May 20. pii: 10.1007/s10549-020-05674.

  45. SCATENA C, Scarpitta R, Innocenti L, Miccoli M, et al
    Androgen receptor expression inversely correlates with histological grade and N stage in ER(+)/PgR(low) male breast cancer.
    Breast Cancer Res Treat. 2020 May 21. pii: 10.1007/s10549-020-05682.
    PubMed         Abstract available

  46. HAO Y, Xu B, Yan Q, Zhou M, et al
    Long-term excess body fat in adulthood and the risk of pre- and postmenopausal breast cancer in Chinese women.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05685.
    PubMed         Abstract available

  47. ZHANG LY, Zhang YQ, Zeng YZ, Zhu JL, et al
    TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05673.
    PubMed         Abstract available

  48. SILVA CL, Perestrelo R, Sousa-Ferreira I, Capelinha F, et al
    Lipid biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Breast Cancer Res Treat. 2020 May 15. pii: 10.1007/s10549-020-05672.
    PubMed         Abstract available

    Breast J

  49. BEN KRIDIS W, Khanfir A
    Delayed docetaxel extravasation in case of breast cancer.
    Breast J. 2020 May 18. doi: 10.1111/tbj.13882.

  50. BAR-SELA G, Samih Y, Yerushalmi R, Leviov M, et al
    Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2-negative breast cancer patients in Israel: A registry analysis.
    Breast J. 2020 May 18. doi: 10.1111/tbj.13870.

  51. TASDOVEN I, Karadeniz Cakmak G
    Breast cancer surgery under the shadow of COVID-19: Quest for optimal axillary management after neo-adjuvant chemotherapy.
    Breast J. 2020 May 20. doi: 10.1111/tbj.13892.

  52. CICCARESE M, Orlando L, Fedele P, Schiavone P, et al
    A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
    Breast J. 2020 May 20. doi: 10.1111/tbj.13856.

    Effects of breast cancer treatment on metabolic health.
    Breast J. 2020 May 16. doi: 10.1111/tbj.13852.


  54. SHARIFI MN, Anandan A, Grogan P, O'Regan RM, et al
    Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
    Cancer. 2020 May 19. doi: 10.1002/cncr.32931.
    PubMed         Abstract available

    Clin Breast Cancer

  55. STATLER AB, Wei W, Gupta A, Blake CN, et al
    Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
    Clin Breast Cancer. 2020 Apr 18. pii: S1526-8209(20)30080.
    PubMed         Abstract available

  56. MUKHERJEE N, Panda CK
    Wnt/beta-Catenin Signaling Pathway as Chemotherapeutic Target in Breast Cancer: An Update on Pros and Cons.
    Clin Breast Cancer. 2020 Apr 18. pii: S1526-8209(20)30082.
    PubMed         Abstract available

  57. ZHANG X, Yang H
    Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer.
    Clin Breast Cancer. 2020 Apr 30. pii: S1526-8209(19)30732.
    PubMed         Abstract available

    Clin Cancer Res

  58. MERIC-BERNSTAM F, Johnson A, Ileana Dumbrava EE, Raghav K, et al
    Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Clin Cancer Res. 2018 Nov 15. pii: 1078-0432.CCR-18-2275.
    PubMed         Abstract available

    Eur J Cancer

  59. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    PubMed         Abstract available

    Int J Cancer

  60. ZAHL PH, Kalager M, Suhrke P, Nord E, et al
    Quality-of-life effects of screening mammography in Norway.
    Int J Cancer. 2020;146:2104-2112.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  61. HO AY, Wright JL, Blitzblau RC, Mutter RW, et al
    Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.
    Int J Radiat Oncol Biol Phys. 2020 May 14. pii: S0360-3016(20)31135.
    PubMed         Abstract available

  62. SPEERS C, Chang SL, Pesch A, Ritter C, et al
    A signature that may be predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences.
    Int J Radiat Oncol Biol Phys. 2020 May 17. pii: S0360-3016(20)31139.
    PubMed         Abstract available

    J Clin Invest

  63. LU H, Xie Y, Tran L, Lan J, et al
    Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.
    J Clin Invest. 2020 May 19. pii: 138577. doi: 10.1172/JCI138577.
    PubMed         Abstract available

    J Natl Cancer Inst

  64. MCCARTHY AM, Armstrong K
    Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838710. doi: 10.1093.

  65. PALMER JR, Polley EC, Hu C, John EM, et al
    Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838706. doi: 10.1093.
    PubMed         Abstract available

    J Surg Oncol

  66. CHENG M, Zhuang X, Zhang L, Zhu T, et al
    A nomogram to predict non-sentinel lymph node metastasis in patients with initial cN+ breast cancer that downstages to cN0 after neoadjuvant chemotherapy.
    J Surg Oncol. 2020 May 20. doi: 10.1002/jso.25989.
    PubMed         Abstract available


  67. DATTACHOUDHURY S, Sharma R, Kumar A, Jaganathan BG, et al
    Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells.
    Oncology. 2020 May 20:1-9. doi: 10.1159/000505521.
    PubMed         Abstract available

    PLoS One

  68. STUEBER TN, Diessner J, Bartmann C, Leinert E, et al
    Effect of adjuvant radiotherapy in elderly patients with breast cancer.
    PLoS One. 2020;15:e0229518.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.